In the Hill Country area, home to Camp Mystic and several other summer camps, searchers have found the bodies of 75 people, ...

The disclosure by U.S. lawyer Jonathan Guynn contradicts statements by spokespeople for the Justice Department and the White ...

The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic ...

Women across the nation have connected online over their unexpected pregnancies, known as "Ozempic babies," while using GLP-1 ...

McALLEN, Texas (AP) — A 27-year-old man was killed Monday after opening fire at a U.S. Border Patrol facility in McAllen, ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

Key Takeaways The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average, compared ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.